title: Structural analogues of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors.
abstract: Several structural analogues of 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin (5-OMe-BPAT, 1), a representative of a series of 2-aminotetralin-derived benzamides with potential atypical antipsychotic properties, were synthesized and evaluated for their ability to bind to dopamine D2A, D3, and serotonin 5-HT1A receptors in vitro. The structure affinity relationships revealed that the aromatic ring of the benzamide moiety of 1 contributes to the high affinities for all three receptor subtypes. Furthermore, 1 may interact with the dopamine D2 and D3 receptors through hydrogen bond formation with its carbonyl group. Investigation of the role of the amide hydrogen atom by amide N-alkylation was not conclusive, since conformational aspects may be responsible for the decreased dopaminergic affinities of the N'-alkylated analogues of 1. The effects of the amide modifications on the serotonin 5-HT1A receptor affinity were less pronounced, suggesting that the benzamidoethyl side-chain of 1 as a whole enhances the affinity for this receptor subtype probably through hydrophobic interactions with an accessory binding site. The structural requirements for the substituents at the basic nitrogen atom supported the hypothesis that the 2-aminotetralin moieties of the 2-aminotetralin-derived substituted benzamides may share the same binding sites as the 2-(N,N-di-n-propylamino)tetralins.
authors.affiliation: Department of Medicinal Chemistry, University Centre for Pharmacy, University of Groningen, The Netherlands. ejhoman@pharmacop.com
authors.forename: E J
authors.initials: EJ
authors.lastname: Homan
authors.forename: E
authors.initials: E
authors.lastname: Kroodsma
authors.forename: S
authors.initials: S
authors.lastname: Copinga
authors.forename: L
authors.initials: L
authors.lastname: Unelius
authors.forename: N
authors.initials: N
authors.lastname: Mohell
authors.forename: H V
authors.initials: HV
authors.lastname: Wikström
authors.forename: C J
authors.initials: CJ
authors.lastname: Grol
mesh_terms: D000818:Animals; D001549:Benzamides / Q000737:chemistry* / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D015259:Dopamine Agents / Q000737:chemistry* / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D051381:Rats; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin / Q000378:metabolism*; D044263:Receptors, Serotonin, 5-HT1; D018490:Serotonin Agents / Q000737:chemistry* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013764:Tetrahydronaphthalenes / Q000737:chemistry* / Q000378:metabolism
chemical_list: C120949:5-methoxy-2-(N-(2-benzamidoethyl)-N-n-propylamino)tetralin; D001549:Benzamides; C493593:DRD3 protein, human; D015259:Dopamine Agents; C493595:Drd3 protein, rat; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D018490:Serotonin Agents; D013764:Tetrahydronaphthalenes